Pfizer Halts Development of Twice-Daily Weight Loss Pill Due to Adverse Side Effects

Despite the setback, the pharmaceutical giant plans to release data on a once-daily version of the pill next year.

Pfizer has halted the development of its twice-daily weight loss pill, danuglipron, due to high rates of adverse side effects in a midstage clinical trial.
The side effects experienced by patients included gastrointestinal issues such as nausea, diarrhea, and vomiting.
Despite the setback, Pfizer plans to release data on a once-daily version of the pill next year, which will inform the path forward.
The discontinuation of danuglipron trials led to a 4% drop in Pfizer's stock.
The pharmaceutical industry has struggled to develop safe and effective weight loss treatments, with many previous drugs being scrapped due to unintended side effects.